Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Special drug-use survey of Tarlige in central neuropathic pain
jRCT2031220132Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of mirogabalin in central neuropathic pain (CNP), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Occurrence of adverse drug reactions stratified by causative diseases of neuropathic pain. Started Jul 2022; status: active, not recruiting.
02
Drugs
mirogabalin
03
Conditions
central neuropathic pain (CNP)
Beyond the preview
Go deeper on jRCT2031220132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220132.